Retina

17-32 of 340

• 

  RestartResume

  It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

  RestartResume

  It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

  CME/CE

  It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

  David Eichenbaum, MD

  0.25 credits

  • 

    

    David Eichenbaum, MD

  0.25 credits

• 

  RestartResume

  Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

  RestartResume

  Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

  CME/CE

  Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

  Deepak Sambhara, MD

  0.25 credits

  • 

    

    Deepak Sambhara, MD

  0.25 credits

• 

  RestartResume

  Anatomical Outcomes from the LIGHTSITE III Trial

  RestartResume

  Anatomical Outcomes from the LIGHTSITE III Trial

  MinuteCE®

  Anatomical Outcomes from the LIGHTSITE III Trial

  Diana V. Do, MD; David Boyer, MD

  1.00 program credit

  • 

    

    Diana V. Do, MD

  • 

    

    David Boyer, MD

  1.00 program credit

• 

  RestartResume

  Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration

  RestartResume

  Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration

  MinuteCE®

  Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration

  Marion Munk, MD, Ph.D; David Boyer, MD

  1.00 program credit

  • 

    

    Marion Munk, MD, Ph.D

  • 

    

    David Boyer, MD

  1.00 program credit

• 

  RestartResume

  Best Practices for Optimized Photobiomodulation Treatment Effect: Candidate Selection

  RestartResume

  Best Practices for Optimized Photobiomodulation Treatment Effect: Candidate Selection

  MinuteCE®

  Best Practices for Optimized Photobiomodulation Treatment Effect: Candidate Selection

  Marion Munk, MD, Ph.D; Diana V. Do, MD

  1.00 program credit

  • 

    

    Marion Munk, MD, Ph.D

  • 

    

    Diana V. Do, MD

  1.00 program credit

• 

  RestartResume

  Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma

  RestartResume

  Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma

  MinuteCE®

  Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma

  Janis T. Eells, Ph.D.

  1.00 program credit

  • 

    

    Janis T. Eells, Ph.D.

  1.00 program credit

• 

  MinuteCE®

  Lighting the Way: Exploring the Potential of Photobiomodulation for Dry AMD Treatment

  Janis T. Eells, Ph.D.; David Boyer, MD

  1.00 credit 8 episodes

  • 

    

    Janis T. Eells, Ph.D.

  • 

    

    David Boyer, MD

  • 

    

    Diana V. Do, MD

  • 

    

    Marion Munk, MD, Ph.D

  1.00 credit 8 episodes

• 

  RestartResume

  Clinical and Safety Outcomes from the LIGHTSITE III Trial

  RestartResume

  Clinical and Safety Outcomes from the LIGHTSITE III Trial

  MinuteCE®

  Clinical and Safety Outcomes from the LIGHTSITE III Trial

  David Boyer, MD; Diana V. Do, MD

  1.00 program credit

  • 

    

    David Boyer, MD

  • 

    

    Diana V. Do, MD

  1.00 program credit

• 

  RestartResume

  Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape

  RestartResume

  Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape

  MinuteCE®

  Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape

  David Boyer, MD; Marion Munk, MD, Ph.D

  1.00 program credit

  • 

    

    David Boyer, MD

  • 

    

    Marion Munk, MD, Ph.D

  1.00 program credit

• 

  RestartResume

  Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice

  RestartResume

  Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice

  MinuteCE®

  Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice

  Diana V. Do, MD; Marion Munk, MD, Ph.D

  1.00 program credit

  • 

    

    Diana V. Do, MD

  • 

    

    Marion Munk, MD, Ph.D

  1.00 program credit

• 

  RestartResume

  Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications

  RestartResume

  Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications

  MinuteCE®

  Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications

  Marion Munk, MD, Ph.D; David Boyer, MD

  1.00 program credit

  • 

    

    Marion Munk, MD, Ph.D

  • 

    

    David Boyer, MD

  1.00 program credit

• 

  RestartResume

  Beyond the First Generation: MAKING REAL-WORLD DECISIONS ABOUT RETINAL THERAPIES

  RestartResume

  Beyond the First Generation: MAKING REAL-WORLD DECISIONS ABOUT RETINAL THERAPIES

  CME/CE

  Beyond the First Generation: MAKING REAL-WORLD DECISIONS ABOUT RETINAL THERAPIES

  Katherine E. Talcott, MD; Ferhina S. Ali, MD, MPH, FASRS

  1.00 credit

  • 

    

    Katherine E. Talcott, MD

  • 

    

    Ferhina S. Ali, MD, MPH, FASRS

  • 

    

    Durga Borkar, MD, MMCi

  • 

    

    Theodore Leng, MD, MS

  • 

    

    Danny Mammo, MD

  • 

    

    Yasha S. Modi, MD, MHS

  1.00 credit

• 

  RestartResume

  Shared Care Perspectives: Retina and Optometry

  RestartResume

  Shared Care Perspectives: Retina and Optometry

  CME/CE

  Shared Care Perspectives: Retina and Optometry

  John Kitchens, MD; Sara LeMay, OD

  0.25 credits

  • 

    

    John Kitchens, MD

  • 

    

    Sara LeMay, OD

  0.25 credits

• 

  RestartResume

  Beyond BCVA: Measuring Functional Vision in MacTel Type 2

  RestartResume

  Beyond BCVA: Measuring Functional Vision in MacTel Type 2

  MinuteCE®

  Beyond BCVA: Measuring Functional Vision in MacTel Type 2

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 program credit

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  1.00 program credit

• 

  RestartResume

  MacTel Type 2: A Misnomer?

  RestartResume

  MacTel Type 2: A Misnomer?

  MinuteCE®

  MacTel Type 2: A Misnomer?

  Dean Eliott, MD; Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit

  • 

    

    Dean Eliott, MD

  • 

    

    Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit

• 

  MinuteCE®

  Rethinking MacTel: Cell-based Insights for Vision Preservation

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 credit 10 episodes

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  • 

    

    Dean Eliott, MD

  • 

    

    Charles C. Wykoff, MD, PhD, FACS

  1.00 credit 10 episodes